Median Technologies announced positive top-line results from its RELIVE study for eyonis™ LCS, an AI-powered lung cancer screening software. The study met its primary endpoint, demonstrating that eyonis™ LCS significantly improves diagnostic accuracy when used in conjunction with radiologists compared to radiologists alone. This achievement follows the successful completion of the REALITY study and paves the way for regulatory submissions in the U.S. and EU in Q2 2025.

This news is vital because it addresses the critical need for early lung cancer detection. The current five-year survival rate for lung cancer is low, primarily because most cases are diagnosed at late stages. Eyonis™ LCS has the potential to increase early detection rates, thereby improving patient outcomes and potentially reducing healthcare costs associated with late-stage treatment. Improved accuracy in lung cancer screening can also minimize unnecessary follow-up procedures for healthy individuals, further reducing healthcare expenditures and patient anxiety.

The RELIVE study, conducted with 480 high-risk patients, showed that eyonis™ LCS improved radiologists’ ability to detect, localize, and characterize lung nodules. This translated to a statistically significant improvement in diagnostic accuracy (p=0.027). The company is currently analyzing secondary endpoints and will release additional data in the near future. The earlier REALITY study, with 1,147 patients, demonstrated eyonis™ LCS’s capability to differentiate between cancerous and non-cancerous patients and characterize suspicious nodules. Both studies utilized retrospective data from major cancer centers and hospitals in the U.S. and EU. Median Technologies is targeting a large addressable market, with 14.5 million people in the U.S. currently eligible for lung cancer screening under Medicare.

The positive results from RELIVE solidify the potential of eyonis™ LCS to transform lung cancer screening. Pending regulatory approvals, this technology could become a crucial tool for healthcare professionals, enabling earlier and more accurate diagnoses, leading to better patient outcomes and a potential reduction in healthcare costs. This could also impact global healthcare systems as lung screening programs expand in Europe and Asia.

Source link: http://www.businesswire.com/news/home/20250202966747/en/Median-Technologies-eyonis%E2%84%A2-Lung-Cancer-Screening-LCS-Meets-Primary-Endpoint-in-RELIVE-Clinical-Trial-the-Final-Pivotal-Study-Required-for-Regulatory-Submissions

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.